


10/540367

"Express Mail" Mailing label number: EV 143571334 US

Date of Deposit June 23, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

  
Regina D. McKinney

37 CFR 1.10  
23 JUN 2005

Docket No.: SJ-02-0015A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julia HURWITZ; Karen SLOBOD; Allen PORTNER;  
Christopher COLECLOUGH

Serial No.: t/b/a (U.S. National Phase of International Application No.

PCT/US2004/000635 filed January 12, 2004)

Filed: Concurrently Herewith

For: USE OF SENDAI VIRUS AS A HUMAN PARAINFLUENZA VACCINE

-----  
**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97**

Sir:

Attached is a list of documents on form PTO/SB/08A. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

No fees for consideration of this statement beyond those provided for in documents accompanying this paper are believed to be necessary. However, in the event that additional fees are necessary to allow consideration of this paper, such fees

10/540367

JC20 Rec'd PCP/PJO 23 JUN 2005

required therefore (including fees for net addition of claims) are hereby authorized to be charged to Deposit Account No. 501968.

Respectfully submitted,



J. Scott Elmer  
Attorney/Agent for Application  
Registration No. 36,129

JC20 Rec'd PCT/PTO 23 JUN 2005  
PTO/SB/08

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

She

1

of 2

<i>Complete if Known</i>	
Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Hurwitz, et.al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	SJ-02-0015A

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered
-----------------------	--	--------------------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				101540367	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number			
		Filing Date		Herewith	
		First Named Inventor		Hurwitz, et.al.	
		Art Unit		Unknown	
		Examiner Name		Unknown	
Sheet	2	of	2	Attorney Docket Number	SJ-02-0015A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C1	HURWITZ, J.L., et al; "Intranasal Sendai virus vaccine protects African green monkeys from infection with human parainfluenza virus-type one"; Vaccine 15:533-540 (1997)		
	C2	GORMAN, W.L., et al; "The Hemagglutinin-Neuraminidase Glycoproteins of Human Parainfluenza Virus Type 1 and Sendai Virus have high structure-function similarity		
		with limited Antigenic cross-reactivity"; Virology 175:211-221 (1990)		
	C3	SANGSTER, M., et al; "Human Parainfluenza Type 1 Immunization of Infant Mice Protects from Subsequent Sendai Virus Infection"; Virology 212:13-19 (1995)		
	C4	SKIADOPoulos, M.H., et al; "Sendai Virus, a Murine Parainfluenza Virus Type 1, Replicates to a Level Similar to Human PIV1 in the Upper and Lower Respiratory Tract of		
		African Green Monkey and Chimpanzees"; Virology 297:153-160 (2002)		
	C5	VAN WYKE COELINGH, K.L., et al.; "Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3		
		Challenge"; J Inf Dis 157:655-662 (1988)		
	C6	WANG, X-L, et al.; "A Protease Activation Mutant, MVCES1, as a Safe and Potent Live Vaccine Derived from Currently Prevailing Sendai Virus"; J Viro 68:3369-3373 (1994)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.